<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2523">
  <stage>Registered</stage>
  <submitdate>8/10/2009</submitdate>
  <approvaldate>8/10/2009</approvaldate>
  <nctid>NCT00992381</nctid>
  <trial_identification>
    <studytitle>Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone</studytitle>
    <scientifictitle>A Single Centre, Two Treatment, Two Period, Two Sequence, Randomized Crossover Steady-state Relative Bioavailability Study of Naproxen in Two Tablet Formulations Given Twice Daily (PN 400 Tablets Containing 500 mg of Naproxen Plus 20 mg of Esomeprazole Versus Naprosyn® Containing Naproxen 500 mg)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D1120C00035</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PN400
Treatment: drugs - Naprosyn

Experimental: 1 - PN400

Active Comparator: 2 - Naproxen


Treatment: drugs: PN400
500mg Naproxen and 20mg esomeprazole

Treatment: drugs: Naprosyn
500mg Naproxen

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the relative naproxen bioavailability of PN 400 (naproxen 500 mg plus esomeprazole 20 mg) compared to an immediate release Naprosyn® 500 mg tablet</outcome>
      <timepoint>blood samples taken at various time points over 2 treatment periods of 11 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the pharmacokinetic (PK) properties of the naproxen component of PN 400 tablet and immediate release Naprosyn® 500 mg tablet,</outcome>
      <timepoint>Blood samples taken at various time point over 2 periods of 2 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the adverse event profile of PN 400 with that from Naprosyn®</outcome>
      <timepoint>Adverse event reporting over 2 periods of 11 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects must have a body weight greater than 50 kg and BMI within the range
             18-30(inclusive).

          -  Subjects must be in good health, as assessed during pre-study medical examination and
             by review of screening results

          -  Subjects must understand the procedures involved and agree to participate in the study
             by giving fully informed, written consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Significant intercurrent disease of any type, in particular liver, kidney,
             cardiovascular disease, any form of diabetes or significant gastrointestinal disorder
             which could affect drug absorption, or any history of gastric or duodenal ulceration.

          -  Ingestion of any naproxen, omeprazole, esomeprazole or related drugs prior to the
             recruitment interview, such that these drugs will have been ingested in the 4 weeks
             prior to the day set for the first Period 1 dose</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Research Site - Brisbane</hospital>
    <postcode> - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>POZEN</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether the absorption of naproxen from the PN 400
      combination (Naprosyn and Esomeprazole) tablets is similar to that from the naproxen tablets
      (Naprosyn®), which are currently sold in Australia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00992381</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Terry Hurst</name>
      <address>Q-Pharm Phase one unit</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>